Abstract
Within the ambit of the National Mental Health Program, the Government of India has mandated long-acting risperidone, a patented molecule of Janssen Pharmaceutica. We contest that the healthcare system of India is ill-equipped (due to its weak infrastructure) to monitor side effects, regulate the use, and ensure informed consent. The process of including patented Risperdal Consta into the Indian formulary has lacked transparency and suggests undo favor towards Janssen. Janssen Pharmaceutica is known for its aggressive marketing strategy resulting in off-label use of oral risperidone in the US. Moreover, the lax regulatory structure for pharmaceutical dispensing in India coupled with Janssen’s aggressive marketing is a potential cause of concern. We are critical of the decision to include a costly and patented molecule in a publicly financed health program otherwise sourced by generic drugs.
This is a preview of subscription content, log in via an institution to check access.
References
Agrawal, S. (2017). Risking health of its women, India uses controversial contraceptive in family planning programme. IndiaSpend: Health & Sanitation [Internet]. Retrieved Nov 19, 2019, from https://archive.indiaspend.com/cover-story/risking-health-of-its-women-india-uses-controversial-contraceptive-in-family-planning-programme-36857
Barry, E., & Dugger, C.W. (2016). India to change its decades-old reliance on female sterilization. New York Times: Asia Pacific [Internet]. Retrieved Feb 10, 2019, from https://www.nytimes.com/2016/02/21/world/asia/india-to-change-its-decades-old-reliance-on-female-sterilization.html
Brill, S. (2015). America’s most admired lawbreaker. Huffington Post [Internet]. Retrieved Nov 19, 2019, from https://highline.huffingtonpost.com/miracleindustry/americas-most-admired-lawbreaker/
Covell, N. H., McEvoy, J. P., Schooler, N. R., Stroup, T. S., Jackson, C. T., Rojas, I. A., & Essock, S. M. (2012). Schizophrenia trials network. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: An open-label, randomized controlled trial. Journal of Clinical Psychiatry, 73(5), 669–675.
Das, A. (2014). The context of formulation of India’s mental health program: Implications for global mental health. Asian Journal of Psychiatry, 7, 10–14.
Duffy, R. M., & Kelly, B. D. (2019). The right to mental healthcare: India moves forward. British Journal of Psychiatry, 214(2), 59–60. https://doi.org/10.1192/bjp.2018.250.
Ecks, S., & Basu, S. (2009). How wide is the ‘Treatment Gap’ for antidepressants in India? Ethnographic insights on private industry marketing strategies. Journal of Health Studies, 2, 68–80.
Government of India, Ministry of Health & Family Welfare. (2015). Guidelines for implementing district level activities under the National Mental Health Programme (NMHP) during the 12th Plan period [Internet]. Retrieved Jan 26, 2019, from https://mohfw.gov.in/sites/default/files/56464578341436263710_0_0.pdf
Government of India, Ministry of Health & Family Welfare. (2018). List of psychotherapeutic drugs/medicines that should be available at district hospital/CHC/PHC levels [Internet]. Retrieved Dec 12, 2019, from https://mohfw.gov.in/sites/default/files/Pages%20from%20Drugs%20List.pdf
Hartmann, B., & Rao, M. (2015). India’s population programme: Obstacles and opportunities. Economic & Political Weekly, 50(44), 10–13.
Janssen. (2019). Risperdal Consta [package insert]. Titusville (NJ).
Mental Health Policy Group. (2012). XIIth plan district mental health programme. Mental Health Policy Group, New Delhi [Internet]. Retrieved Nov 12, 2019, from https://mhpolicy.files.wordpress.com/2012/07/final-dmhp-design-xii-plan2.pdf
Ministry of Health and Family Welfare. (2016). Government of India. Annual Report 2015–16. Other National Health Programmes [Internet]. Retrieved Nov 7, 2020, from https://main.mohfw.gov.in/sites/default/files/78963256452123365785.pdf
Mitchell, A. J., Malone, D., & Doebbeling, C. C. (2009). Quality of medical care for people with and without comorbid mental illness and substance misuse: Systematic review of comparative studies. British Journal of Psychiatry, 194, 491–499. https://doi.org/10.1192/bjp.bp.107.045732.
The Mental Health Care Act 2017 (India).
World Health Organization. (2018). mhGAP operations manual: Mental health gap action programme (mhGAP) [Internet]. Geneva: World Health Organization Retrieved Nov 19, 2019, from https://apps.who.int/iris/bitstream/handle/10665/275386/9789241514811-eng.pdf?ua=1.
Funding
Funding source had no involvement in writing this article. The authors have no relevant financial or non-financial interests to disclose. No funds, grants, or other support was received.
Author information
Authors and Affiliations
Contributions
AD is the sole contributor to the conceptualization, writing, editing and review of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
I declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Rights and permissions
About this article
Cite this article
Das, A. Janssen Pharmaceutica, Long-Acting Risperidone and Public Health Program of India. Community Ment Health J 57, 792–795 (2021). https://doi.org/10.1007/s10597-020-00762-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10597-020-00762-w